nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—autonomic nervous system—conduct disorder	0.206	0.57	CbGeAlD
Loperamide—CALM1—autonomic nervous system—conduct disorder	0.0559	0.155	CbGeAlD
Loperamide—POMC—brain—conduct disorder	0.0199	0.0551	CbGeAlD
Loperamide—CACNA1A—brain—conduct disorder	0.019	0.0526	CbGeAlD
Loperamide—OPRD1—brain—conduct disorder	0.011	0.0304	CbGeAlD
Loperamide—OPRK1—brain—conduct disorder	0.0105	0.0292	CbGeAlD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00787	0.0125	CbGpPWpGaD
Loperamide—OPRM1—brain—conduct disorder	0.00749	0.0207	CbGeAlD
Loperamide—Haloperidol—DRD4—conduct disorder	0.00708	0.684	CrCbGaD
Loperamide—CACNA1A—Neuronal System—GABRA2—conduct disorder	0.00699	0.0111	CbGpPWpGaD
Loperamide—CALM3—brain—conduct disorder	0.00692	0.0192	CbGeAlD
Loperamide—POMC—GPCR ligand binding—CGA—conduct disorder	0.00599	0.00953	CbGpPWpGaD
Loperamide—POMC—Biological oxidations—COMT—conduct disorder	0.00573	0.00912	CbGpPWpGaD
Loperamide—POMC—Biological oxidations—MAOA—conduct disorder	0.00569	0.00905	CbGpPWpGaD
Loperamide—POMC—G alpha (i) signalling events—DRD4—conduct disorder	0.00554	0.00881	CbGpPWpGaD
Loperamide—CALM2—brain—conduct disorder	0.00543	0.0151	CbGeAlD
Loperamide—CALM1—brain—conduct disorder	0.00541	0.015	CbGeAlD
Loperamide—POMC—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00488	0.00776	CbGpPWpGaD
Loperamide—CYP2C8—brain—conduct disorder	0.0045	0.0125	CbGeAlD
Loperamide—POMC—Glucocorticoid receptor regulatory network—EP300—conduct disorder	0.00445	0.00707	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0044	0.00701	CbGpPWpGaD
Loperamide—CACNA1A—Transmission across Chemical Synapses—COMT—conduct disorder	0.00439	0.00698	CbGpPWpGaD
Loperamide—CACNA1A—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00436	0.00694	CbGpPWpGaD
Loperamide—POMC—Metabolism of proteins—CGA—conduct disorder	0.00421	0.0067	CbGpPWpGaD
Loperamide—CALM2—Melatonin metabolism and effects—MAOA—conduct disorder	0.00416	0.00662	CbGpPWpGaD
Loperamide—CALM1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00416	0.00662	CbGpPWpGaD
Loperamide—CYP2B6—brain—conduct disorder	0.00404	0.0112	CbGeAlD
Loperamide—POMC—GPCR downstream signaling—CGA—conduct disorder	0.00338	0.00538	CbGpPWpGaD
Loperamide—CACNA1A—Neuronal System—COMT—conduct disorder	0.00336	0.00535	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—DRD4—conduct disorder	0.00335	0.00534	CbGpPWpGaD
Loperamide—CACNA1A—Neuronal System—MAOA—conduct disorder	0.00334	0.00531	CbGpPWpGaD
Loperamide—Haloperidol—HTR2A—conduct disorder	0.00326	0.316	CrCbGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00312	0.00496	CbGpPWpGaD
Loperamide—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.00307	0.00489	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—CGA—conduct disorder	0.00307	0.00489	CbGpPWpGaD
Loperamide—CYP2D6—brain—conduct disorder	0.003	0.00831	CbGeAlD
Loperamide—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00296	0.00472	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00287	0.00457	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00274	0.00435	CbGpPWpGaD
Loperamide—CALM3—VEGFA-VEGFR2 Pathway—WASF1—conduct disorder	0.00271	0.00431	CbGpPWpGaD
Loperamide—CALM2—VEGFA-VEGFR2 Pathway—WASF1—conduct disorder	0.00262	0.00417	CbGpPWpGaD
Loperamide—CALM1—VEGFA-VEGFR2 Pathway—WASF1—conduct disorder	0.00262	0.00417	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—WASF1—conduct disorder	0.00256	0.00407	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.00256	0.00407	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—WASF1—conduct disorder	0.00247	0.00393	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—WASF1—conduct disorder	0.00247	0.00393	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.00247	0.00393	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.00247	0.00393	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—CGA—conduct disorder	0.00238	0.00378	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00231	0.00368	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—DRD4—conduct disorder	0.0022	0.0035	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—HTR2A—conduct disorder	0.00219	0.00348	CbGpPWpGaD
Loperamide—POMC—Metabolism—CGA—conduct disorder	0.00217	0.00345	CbGpPWpGaD
Loperamide—ABCB1—brain—conduct disorder	0.00216	0.00598	CbGeAlD
Loperamide—OPRK1—GPCR ligand binding—CGA—conduct disorder	0.00208	0.00332	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00204	0.00325	CbGpPWpGaD
Loperamide—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.002	0.00319	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—DRD4—conduct disorder	0.00193	0.00307	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.00192	0.00306	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—DRD4—conduct disorder	0.0019	0.00302	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—CGA—conduct disorder	0.00188	0.00299	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.00186	0.00296	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.00186	0.00296	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—CGA—conduct disorder	0.00182	0.00289	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00179	0.00285	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—CGA—conduct disorder	0.00176	0.0028	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00175	0.00278	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—DRD4—conduct disorder	0.00172	0.00274	CbGpPWpGaD
Loperamide—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0017	0.0027	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—DRD4—conduct disorder	0.00163	0.00259	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00153	0.00244	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00151	0.00241	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—GABRA2—conduct disorder	0.00147	0.00234	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—WASF1—conduct disorder	0.00146	0.00231	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—GABRA2—conduct disorder	0.00142	0.00227	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—GABRA2—conduct disorder	0.00142	0.00227	CbGpPWpGaD
Loperamide—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00139	0.00222	CbGpPWpGaD
Loperamide—CALM3—IFN-gamma pathway—EP300—conduct disorder	0.00136	0.00216	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—CGA—conduct disorder	0.00134	0.00214	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00133	0.00212	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—DRD4—conduct disorder	0.00133	0.00212	CbGpPWpGaD
Loperamide—CALM2—IFN-gamma pathway—EP300—conduct disorder	0.00131	0.00209	CbGpPWpGaD
Loperamide—CALM1—IFN-gamma pathway—EP300—conduct disorder	0.00131	0.00209	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0013	0.00206	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—HTR2A—conduct disorder	0.00124	0.00197	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—CGA—conduct disorder	0.00122	0.00194	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—CGA—conduct disorder	0.00118	0.00187	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00117	0.00186	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—DRD4—conduct disorder	0.00117	0.00186	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00114	0.00181	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—MB21D1—conduct disorder	0.00114	0.00181	CbGpPWpGaD
Loperamide—CALM3—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—conduct disorder	0.00113	0.0018	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—HTR2A—conduct disorder	0.00112	0.00179	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—MB21D1—conduct disorder	0.0011	0.00175	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—MB21D1—conduct disorder	0.0011	0.00175	CbGpPWpGaD
Loperamide—CALM1—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—conduct disorder	0.00109	0.00174	CbGpPWpGaD
Loperamide—CALM2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—conduct disorder	0.00109	0.00174	CbGpPWpGaD
Loperamide—CYP2B6—Biological oxidations—COMT—conduct disorder	0.00107	0.00171	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CGA—conduct disorder	0.00107	0.0017	CbGpPWpGaD
Loperamide—CYP2B6—Biological oxidations—MAOA—conduct disorder	0.00106	0.00169	CbGpPWpGaD
Loperamide—CYP2B6—Metapathway biotransformation—COMT—conduct disorder	0.00106	0.00168	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—DRD4—conduct disorder	0.00102	0.00162	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.001	0.00159	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CGA—conduct disorder	0.000995	0.00158	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000986	0.00157	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—DRD4—conduct disorder	0.000986	0.00157	CbGpPWpGaD
Loperamide—POMC—Metabolism—COMT—conduct disorder	0.00098	0.00156	CbGpPWpGaD
Loperamide—POMC—Metabolism—MAOA—conduct disorder	0.000973	0.00155	CbGpPWpGaD
Loperamide—POMC—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000944	0.0015	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—COMT—conduct disorder	0.000925	0.00147	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000918	0.00146	CbGpPWpGaD
Loperamide—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000911	0.00145	CbGpPWpGaD
Loperamide—CYP2C8—Biological oxidations—COMT—conduct disorder	0.000908	0.00144	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CGA—conduct disorder	0.000904	0.00144	CbGpPWpGaD
Loperamide—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.000901	0.00143	CbGpPWpGaD
Loperamide—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.000895	0.00142	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—COMT—conduct disorder	0.000895	0.00142	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—COMT—conduct disorder	0.000895	0.00142	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000888	0.00141	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000888	0.00141	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—HTR2A—conduct disorder	0.000868	0.00138	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—COMT—conduct disorder	0.000847	0.00135	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000845	0.00134	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—MAOA—conduct disorder	0.000841	0.00134	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—POLR3A—conduct disorder	0.000836	0.00133	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—POLR3A—conduct disorder	0.000809	0.00129	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—POLR3A—conduct disorder	0.000809	0.00129	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000772	0.00123	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—HTR2A—conduct disorder	0.000762	0.00121	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—DRD4—conduct disorder	0.000752	0.0012	CbGpPWpGaD
Loperamide—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000745	0.00119	CbGpPWpGaD
Loperamide—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00074	0.00118	CbGpPWpGaD
Loperamide—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000735	0.00117	CbGpPWpGaD
Loperamide—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00073	0.00116	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CGA—conduct disorder	0.000721	0.00115	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—COMT—conduct disorder	0.000709	0.00113	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—MAOA—conduct disorder	0.000704	0.00112	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—WASF1—conduct disorder	0.000703	0.00112	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—COMT—conduct disorder	0.000685	0.00109	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—COMT—conduct disorder	0.000685	0.00109	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—DRD4—conduct disorder	0.000683	0.00109	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—MAOA—conduct disorder	0.000681	0.00108	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—MAOA—conduct disorder	0.000681	0.00108	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—WASF1—conduct disorder	0.000681	0.00108	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—WASF1—conduct disorder	0.000681	0.00108	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—HTR2A—conduct disorder	0.000663	0.00106	CbGpPWpGaD
Loperamide—CALM3—Immune System—MB21D1—conduct disorder	0.000663	0.00105	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—DRD4—conduct disorder	0.00066	0.00105	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—HTR2A—conduct disorder	0.000644	0.00102	CbGpPWpGaD
Loperamide—CALM2—Immune System—MB21D1—conduct disorder	0.000642	0.00102	CbGpPWpGaD
Loperamide—CALM1—Immune System—MB21D1—conduct disorder	0.000642	0.00102	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CGA—conduct disorder	0.000632	0.00101	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.0006	0.000954	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—DRD4—conduct disorder	0.000599	0.000953	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—WASF1—conduct disorder	0.000577	0.000919	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CGA—conduct disorder	0.00056	0.00089	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—DRD4—conduct disorder	0.000557	0.000887	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CGA—conduct disorder	0.000541	0.000861	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CGA—conduct disorder	0.000541	0.000861	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CGA—conduct disorder	0.000534	0.000849	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—WASF1—conduct disorder	0.000506	0.000805	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—DRD4—conduct disorder	0.000506	0.000805	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—HTR2A—conduct disorder	0.000491	0.000781	CbGpPWpGaD
Loperamide—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000487	0.000775	CbGpPWpGaD
Loperamide—CALM3—Immune System—POLR3A—conduct disorder	0.000487	0.000774	CbGpPWpGaD
Loperamide—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000484	0.00077	CbGpPWpGaD
Loperamide—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000481	0.000764	CbGpPWpGaD
Loperamide—CALM1—Immune System—POLR3A—conduct disorder	0.000471	0.000749	CbGpPWpGaD
Loperamide—CALM2—Immune System—POLR3A—conduct disorder	0.000471	0.000749	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HTR2A—conduct disorder	0.000446	0.000709	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—HTR2A—conduct disorder	0.00043	0.000685	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—WASF1—conduct disorder	0.000428	0.000681	CbGpPWpGaD
Loperamide—POMC—Metabolism—EP300—conduct disorder	0.00042	0.000669	CbGpPWpGaD
Loperamide—CALM3—Immune System—WASF1—conduct disorder	0.00041	0.000652	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CGA—conduct disorder	0.000406	0.000646	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—DRD4—conduct disorder	0.000404	0.000642	CbGpPWpGaD
Loperamide—CALM2—Immune System—WASF1—conduct disorder	0.000396	0.00063	CbGpPWpGaD
Loperamide—CALM1—Immune System—WASF1—conduct disorder	0.000396	0.00063	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CGA—conduct disorder	0.000395	0.000629	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HTR2A—conduct disorder	0.000391	0.000622	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CGA—conduct disorder	0.000382	0.000608	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CGA—conduct disorder	0.000382	0.000608	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000364	0.000579	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—EP300—conduct disorder	0.000363	0.000578	CbGpPWpGaD
Loperamide—CALM3—RNF mutants show enhanced WNT signaling and proliferation—EP300—conduct disorder	0.000358	0.00057	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—DRD4—conduct disorder	0.000354	0.000563	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—EP300—conduct disorder	0.000351	0.000559	CbGpPWpGaD
Loperamide—CALM1—RNF mutants show enhanced WNT signaling and proliferation—EP300—conduct disorder	0.000347	0.000551	CbGpPWpGaD
Loperamide—CALM2—RNF mutants show enhanced WNT signaling and proliferation—EP300—conduct disorder	0.000347	0.000551	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CGA—conduct disorder	0.000344	0.000547	CbGpPWpGaD
Loperamide—CALM3—Signaling by WNT in cancer—EP300—conduct disorder	0.000333	0.000529	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CGA—conduct disorder	0.000331	0.000526	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00033	0.000525	CbGpPWpGaD
Loperamide—CALM2—Signaling by WNT in cancer—EP300—conduct disorder	0.000322	0.000512	CbGpPWpGaD
Loperamide—CALM1—Signaling by WNT in cancer—EP300—conduct disorder	0.000322	0.000512	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CGA—conduct disorder	0.00032	0.000509	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CGA—conduct disorder	0.00032	0.000509	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—DRD4—conduct disorder	0.000313	0.000498	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000312	0.000496	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—DRD4—conduct disorder	0.000303	0.000482	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—DRD4—conduct disorder	0.000303	0.000482	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CGA—conduct disorder	0.0003	0.000477	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—DRD4—conduct disorder	0.000299	0.000476	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CGA—conduct disorder	0.000282	0.000449	CbGpPWpGaD
Loperamide—CALM3—Signaling by Wnt—EP300—conduct disorder	0.000274	0.000436	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—EP300—conduct disorder	0.000265	0.000422	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—EP300—conduct disorder	0.000265	0.000422	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—WASF1—conduct disorder	0.000265	0.000421	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HTR2A—conduct disorder	0.000263	0.000419	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—WASF1—conduct disorder	0.000256	0.000408	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—WASF1—conduct disorder	0.000256	0.000408	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HTR2A—conduct disorder	0.000231	0.000367	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HTR2A—conduct disorder	0.000204	0.000325	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HTR2A—conduct disorder	0.000198	0.000315	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HTR2A—conduct disorder	0.000198	0.000315	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HTR2A—conduct disorder	0.000195	0.00031	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—EP300—conduct disorder	0.000189	0.0003	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—DRD4—conduct disorder	0.000185	0.000294	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CGA—conduct disorder	0.000185	0.000294	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—COMT—conduct disorder	0.000183	0.000292	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—EP300—conduct disorder	0.000183	0.00029	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—EP300—conduct disorder	0.000183	0.00029	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—MAOA—conduct disorder	0.000182	0.00029	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DRD4—conduct disorder	0.000179	0.000285	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DRD4—conduct disorder	0.000179	0.000285	CbGpPWpGaD
Loperamide—CALM3—Metabolism—COMT—conduct disorder	0.000178	0.000284	CbGpPWpGaD
Loperamide—CALM3—Metabolism—MAOA—conduct disorder	0.000177	0.000282	CbGpPWpGaD
Loperamide—CALM2—Metabolism—COMT—conduct disorder	0.000173	0.000275	CbGpPWpGaD
Loperamide—CALM1—Metabolism—COMT—conduct disorder	0.000173	0.000275	CbGpPWpGaD
Loperamide—CALM2—Metabolism—MAOA—conduct disorder	0.000171	0.000273	CbGpPWpGaD
Loperamide—CALM1—Metabolism—MAOA—conduct disorder	0.000171	0.000273	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—EP300—conduct disorder	0.00017	0.00027	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—EP300—conduct disorder	0.000164	0.000261	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—EP300—conduct disorder	0.000164	0.000261	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—COMT—conduct disorder	0.000155	0.000247	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MAOA—conduct disorder	0.000154	0.000245	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000149	0.000238	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EP300—conduct disorder	0.000139	0.000222	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—COMT—conduct disorder	0.000135	0.000215	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MAOA—conduct disorder	0.000134	0.000214	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—COMT—conduct disorder	0.000127	0.000203	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MAOA—conduct disorder	0.000127	0.000201	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EP300—conduct disorder	0.000122	0.000195	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HTR2A—conduct disorder	0.000121	0.000192	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HTR2A—conduct disorder	0.000117	0.000186	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HTR2A—conduct disorder	0.000117	0.000186	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EP300—conduct disorder	0.000103	0.000164	CbGpPWpGaD
Loperamide—CALM3—Immune System—EP300—conduct disorder	9.9e-05	0.000157	CbGpPWpGaD
Loperamide—CALM2—Immune System—EP300—conduct disorder	9.57e-05	0.000152	CbGpPWpGaD
Loperamide—CALM1—Immune System—EP300—conduct disorder	9.57e-05	0.000152	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—conduct disorder	9.14e-05	0.000145	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—conduct disorder	8.84e-05	0.000141	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—conduct disorder	8.84e-05	0.000141	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—COMT—conduct disorder	8.33e-05	0.000133	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MAOA—conduct disorder	8.27e-05	0.000132	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—conduct disorder	7.86e-05	0.000125	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—conduct disorder	7.65e-05	0.000122	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—conduct disorder	7.4e-05	0.000118	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—conduct disorder	7.4e-05	0.000118	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—conduct disorder	6.66e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—conduct disorder	6.4e-05	0.000102	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—conduct disorder	6.19e-05	9.85e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—conduct disorder	6.19e-05	9.85e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—conduct disorder	5.8e-05	9.23e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—conduct disorder	5.47e-05	8.69e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—conduct disorder	3.57e-05	5.68e-05	CbGpPWpGaD
